Peptide LibraryIGF-1 (overview) dosage in published studies and labels
These are the doses used for IGF-1 (overview) in FDA labelling and published clinical studies, reported as each source states them, one row per regimen. They describe what was studied or approved for a specific population. They are not a recommendation, and none of them is a dose for any individual.
Research and educational reference only. This is not medical advice, and no figure on this page is a dosing recommendation.
Last checked against primary sources:
Studied regimens and sources
Recombinant human IGF-1 has an FDA-approved human dosage as mecasermin: 0.04–0.08 mg/kg twice daily by subcutaneous injection, escalated by 0.04 mg/kg per dose to a maximum of 0.12 mg/kg twice daily, given within 20 minutes of a meal. It is approved only for growth failure in children with severe primary IGF-1 deficiency, and the meal requirement exists because IGF-1 causes hypoglycaemia.
| Human dosing established | Yes |
|---|---|
| Studied dose range | 0.04–0.12 mg/kg twice daily (weight-based) |
| Route | Subcutaneous |
| Frequency | Twice daily |
| Duration studied | Continuous while growth failure is being treated |
| Titration | Start at 0.04–0.08 mg/kg twice daily; if tolerated for at least one week, increase by 0.04 mg/kg per dose, to a maximum of 0.12 mg/kg twice daily. |
| Evidence level | FDA Approved |
| Last reviewed | 2026-09-05 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| FDA label — Increlex (Ipsen)FDA-approved label · FDA prescribing information | Paediatric patients aged 2+ with severe primary IGF-1 deficiency, or GH gene deletion with neutralising antibodies to GH | 0.04–0.08 mg/kg twice daily, maximum 0.12 mg/kg twice daily | Subcutaneous | Twice daily, within 20 minutes of a meal or snack; withhold if the meal is omitted | Continuous | Treatment of growth failure | INCRELEX (mecasermin) injection — FDA prescribing information, DailyMed |
| FDA label — Increlex (Eton)FDA-approved label · FDA prescribing information | Same approved population as the reference product | As per the approved labelling | Subcutaneous | Twice daily | — | Treatment of growth failure | INCRELEX (mecasermin) injection — FDA prescribing information (Eton Pharmaceuticals), DailyMed |
Where sources disagree
- Approved dosing is weight-based and twice daily, and the label requires it to be taken within 20 minutes of a meal, withholding the dose if the meal is skipped. That instruction exists because IGF-1 lowers blood glucose. Protocols quoted for performance use routinely omit both the weight basis and the hypoglycaemia precaution.
- The approval covers children with severe primary IGF-1 deficiency, a rare growth disorder. There is no approved indication, and no trial, for IGF-1 in healthy adults for muscle growth or recovery.
- Mecasermin is recombinant human IGF-1. It is not the same molecule as IGF-1 LR3 or IGF-1 DES, which are engineered analogues sold separately and which have no human dosing evidence of their own.